Gilead Sciences Wins EU Marketing Approval for Trodelvy (GILD)

Gilead Sciences (GILD) secured European Commission marketing authorization on June 23, 2026, for its drug Trodelvy (sacituzumab govitecan). The approval is for adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received prior endocrine-based therapy and at least two additional systemic therapies in the advanced setting. This authorization allows Gilead to commercialize Trodelvy across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. The antibody-drug conjugate previously received approval for triple-negative breast cancer. This expanded indication broadens Trodelvy's market potential and represents a significant regulatory milestone for Gilead in Europe.